Department of Radiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China.
Department of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Acad Radiol. 2024 Sep;31(9):3612-3619. doi: 10.1016/j.acra.2024.02.002. Epub 2024 Mar 15.
We aimed to evaluate clinical characteristics and quantitative CT imaging features for the prediction of liver metastases (LMs) in patients with pancreatic neuroendocrine tumors (PNETs).
Patients diagnosed with pathologically confirmed PNETs were included, 133 patients were in the training group, 22 patients in the prospective internal validation group, and 28 patients in the external validation group. Clinical information and quantitative features were collected. The independent variables for predicting LMs were confirmed through the implementation of univariate and multivariate logistic analyses. The diagnostic performance was evaluated by conducting receiver operating characteristic curves for predicting LMs in the training and validation groups.
PNETs with LMs demonstrated significantly larger diameter and lower arterial/portal tumor-parenchymal enhancement ratio, arterial/portal absolute enhancement value (AAE/PAE value) (p < 0.05). After multivariate analyses, A high level of tumor marker (odds ratio (OR): 5.32; 95% CI, 1.54-18.35), maximum diameter larger than 24.6 mm (OR: 7.46; 95% CI, 1.70-32.72), and AAE value ≤ 51 HU (OR: 4.99; 95% CI, 0.93-26.95) were independent positive predictors of LMs in patients with PNETs, with area under curve (AUC) of 0.852 (95%CI, 0.781-0.907). The AUCs for prospective internal and external validation groups were 0.883 (95% CI, 0.686-0.977) and 0.789 (95% CI, 0.602-0.916), respectively.
Tumor marker, maximum diameter and absolute enhancement value in arterial phase were independent predictors with good predictive performance for the prediction of LMs in patients with PNETs. Combining clinical and quantitative features may facilitate the attainment of good predictive precision in predicting LMs.
本研究旨在评估胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumors,PNETs)患者发生肝转移(liver metastases,LMs)的临床特征和定量 CT 成像特征,以便预测 LMs。
纳入经病理证实的 PNETs 患者,其中 133 例患者纳入训练组,22 例患者纳入前瞻性内部验证组,28 例患者纳入外部验证组。收集临床信息和定量特征。采用单因素和多因素逻辑分析确定预测 LMs 的独立变量。通过在训练组和验证组中进行受试者工作特征曲线(receiver operating characteristic curves)评估预测 LMs 的诊断性能。
发生 LMs 的 PNETs 肿瘤直径显著更大,动脉/门脉肿瘤-实质增强比值、动脉/门脉绝对增强值(arterial/portal absolute enhancement value,AAE/PAE value)更低(p<0.05)。多因素分析后,肿瘤标志物水平较高(比值比(odds ratio,OR):5.32;95%置信区间,1.54-18.35)、最大直径大于 24.6mm(OR:7.46;95%置信区间,1.70-32.72)、AAE 值≤51HU(OR:4.99;95%置信区间,0.93-26.95)是 PNETs 患者发生 LMs 的独立阳性预测因素,曲线下面积(area under the curve,AUC)为 0.852(95%置信区间,0.781-0.907)。前瞻性内部和外部验证组的 AUC 分别为 0.883(95%置信区间,0.686-0.977)和 0.789(95%置信区间,0.602-0.916)。
肿瘤标志物、最大直径和动脉期绝对增强值是预测 PNETs 患者发生 LMs 的独立预测因素,具有良好的预测效能。结合临床和定量特征可能有助于提高预测 LMs 的预测精度。